Bioxytran (BIXT) News Today → The “Next Bitcoin”? 10 CENT Crypto Set to Explode (From True Market Insiders) (Ad) Free BIXT Stock Alerts $0.14 0.00 (0.00%) (As of 04/25/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineBIXT: Carbohydrate Drug Design in the Fight Against Virusesmsn.com - March 20 at 6:59 PMBioxytran Announces Preprint of Shingles Case Study Showing Clearance Using a Topical Galectin-3 Antagonistglobenewswire.com - March 6 at 9:00 AMBioxytran’s Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19finance.yahoo.com - February 21 at 1:43 PMBioxytran's Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19globenewswire.com - February 21 at 8:00 AMBioxytran Gets Broad Patent Coverage on 60+ Virusesfinance.yahoo.com - October 24 at 12:55 PMBioxytran Announces Broad Spectrum Antiviral Activity Highlighted in ProLectin-Mfinance.yahoo.com - September 14 at 10:50 AMBioxytran Received IND Application by the FDA for Clinical Trials with ProLectin-M to Treat COVID-19 patientsbenzinga.com - September 6 at 3:53 PMFDA grants clearance to Bioxytran’s IND for Covid-19 trial initiationmsn.com - August 25 at 7:19 AMBioxytran Announces FDA Clearance of its IND Application for ProLectin-M in Clinical Trialsfinance.yahoo.com - August 24 at 4:18 PMBioxytran Initiates a Registrational Trial of Oral ProLectin-M for Mild to Moderate COVID-19 Patientsfinance.yahoo.com - August 8 at 9:00 AMBioxytran Names Leslie Ajayi as Interim CMO and Head of the Medical Advisory Boardfinance.yahoo.com - July 31 at 8:09 AMBioxytran Peer-Reviewed Journal in "Vaccines" Contains Mechanism Capable of Targeting Future COVID-19 Mutationsit.tmcnet.com - June 27 at 9:49 AMBioxytran Peer-Reviewed Journal in “Vaccines” Contains Mechanism Capable of Targeting Future COVID-19 Mutationsfinance.yahoo.com - June 27 at 9:49 AMBioxytran expands institutional investor base with $0.5M equity investmentmsn.com - June 12 at 3:47 PMBioxytran Expands Institutional Investor Base with an additional $500,000 Equity Investmentfinance.yahoo.com - June 12 at 3:47 PMBioxytran Tests Acellular Oxygen Carrier BXT-25 in Pre-Clinical Trialsfinance.yahoo.com - April 19 at 10:42 AMBioxytran Announces Positive Phase 2 Trial Results were Featured in "Vaccines" a Peer-Reviewed Journaltmcnet.com - March 29 at 10:57 PMBioxytran Announces Positive Phase 2 Trial Results were Featured in “Vaccines” a Peer-Reviewed Journalfinance.yahoo.com - March 29 at 7:57 AMBioxytran, Inc. (BIXT) Stock Historical Prices & Data - Yahoo Financefinance.yahoo.com - March 6 at 9:15 AMProLectin-M Demonstrates Significant Activity Against Influenza and Respiratory Syncytial Virusfinance.yahoo.com - February 28 at 10:18 AMNature Reviews Drug Discovery Article Offers Independent Support for ProLectin-I in Fibrosis and ProLectin-M as an Antiviral Drugfinance.yahoo.com - February 22 at 9:41 AMBioxytran to Appear on ClearThink IR’s Virtual Live Eventfinance.yahoo.com - February 14 at 1:13 PMBioxytran drug candidates ProLectin-M and ProLectin-I progressing as COVID-19 treatmentsproactiveinvestors.com - February 8 at 6:56 PMBioxytran Receives Approval to Initiate Trials with ProLectin-Ifinance.yahoo.com - February 6 at 1:51 PMBioxytran Shares Rise 20% on Trial Results for Covid-19 Drugmarketwatch.com - December 28 at 2:26 PMBioxytran chewable drug for COVID-19 meets phase 2 trial's goalsmsn.com - December 28 at 9:26 AMCrystal Research Update Highlights 100% Responders Rate in Mild to Moderate COVID-19 Trialfinance.yahoo.com - December 28 at 9:26 AMBioxytran Establishes Indian Subsidiary in Preparation of Commercializationfinance.yahoo.com - December 14 at 9:27 AMBioxytran Interview at the Emerging Growth Conferencefinance.yahoo.com - December 12 at 6:11 PMBioxytran Gets Approval In India To Optimize Dosage In COVID-19 Patientsmarkets.businessinsider.com - December 8 at 3:36 PMBioxytran Receives Approval to Optimize Dosage in COVID-19 Patientsfinance.yahoo.com - December 8 at 3:36 PMBioxytran, Inc. Announces the Reinitiation of Coverage of Its Stock by Avise Analyticsfinance.yahoo.com - November 22 at 4:01 PMFinancialnewsmedia.com: While COVID-19 Drags On, Biotechs Introduce New Treatments & Vaccines to Combat Subvariantsfinanznachrichten.de - November 16 at 3:55 PMBIOXYTRAN Announces Positive Mid-stage Study Results Of Galectin Antagonist In Covid Patientsmarkets.businessinsider.com - November 16 at 7:54 AMBioxytran Releases Positive Top-line Results from Phase 2 Trial of Galectin Antagonist on COVID-19 Patients in medRxiv Pre-printfinance.yahoo.com - November 16 at 7:54 AMBioxytran Scientific Advisor Releases New Book on Brain Metabolismfinance.yahoo.com - October 25 at 10:25 AMEnding The Pandemic Cycle - Bioxytran’s (BIXT) Galectin Approachseekingalpha.com - September 16 at 10:18 PMBIXT.PK - Bioxytran Inc | Stock Price & Latest News | Reutersreuters.com - August 17 at 8:43 PMNovel Carbohydrate Antiviral Drug Candidate Acts Through Galectin Inhibition to Block SARS-CoV-2 Coronavirusfinance.yahoo.com - August 1 at 9:57 AMBIXT Real-Time Quotesnasdaq.com - January 24 at 8:27 PM Get Bioxytran News Delivered to You Automatically Sign up to receive the latest news and ratings for BIXT and its competitors with MarketBeat's FREE daily newsletter. Email Address These AI trades triggered this morning (545% return) (Ad)If you think a market crash is possible in 2024, I don't know why you're not using this yet. Click Here To Get Your Free Copy BIXT Media Mentions By Week BIXT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BIXT News Sentiment▼0.000.40▲Average Medical News Sentiment BIXT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BIXT Articles This Week▼10▲BIXT Articles Average Week Get Bioxytran News Delivered to You Automatically Sign up to receive the latest news and ratings for BIXT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Lipocine News Today Eyenovia News Today DURECT News Today Iterum Therapeutics News Today Unity Biotechnology News Today Sol-Gel Technologies News Today Forte Biosciences News Today Qilian International Holding Group News Today Enlivex Therapeutics News Today Acasti Pharma News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:BIXT) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsThe World's First "$20 Trillion Drug?"Behind the MarketsI’m afraid WWIII is a very real possibility Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioxytran, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
